We are building a fully-integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, we are developing cell-based cancer immunotherapies based on our CAR and TCR technologies to genetically engineer T cells to recognize and kill cancer cells. Our most advanced product candidate, lisocabtagene maraleucel ("liso-cel"), also known as JCAR017, is in a potential registration trial for the treatment of relapsed or refractory ("r/r") diffuse large b cell lymphoma ("DLBCL"), and we began a Phase I/II trial with JCAR017 in r/r chronic lymphocytic leukemia ("CLL") in 2017. We have shown compelling clinical responses in clinical trials using multiple cell-based product candidates to address refractory B cell lymphomas and leukemias, and we also have a number of ongoing trials exploring our platform in multiple myeloma and solid-organ cancers and in combination with various strategies to overcome the immune-suppressive effects of cancer. In aggregate, we currently have product candidates in clinical trials targeting eight different protein targets in various cancers. Longer term, we aim to improve and leverage our cell-based platform to develop additional product candidates to address a broad range of cancers and human diseases including moving forward our preclinical product candidates that target additional hematologic and solid-organ cancers. Cancer is a leading cause of death in developed countries. Cancer is characterized by the uncontrolled proliferation of abnormal cells. Cancer cells contain mutated proteins and may overexpress other proteins normally found in the body at low levels. The
Company profile
Website
CEO
Hans E. Bishop
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
16 Apr 18
15-12B
Securities registration termination
16 Mar 18
25-NSE
Exchange delisting
6 Mar 18
8-K
Completion of Acquisition or Disposition of Assets
6 Mar 18
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 18
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 18
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 18
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 18
SC 13E3/A
Going private transaction (amended)
5 Mar 18
SC 14D9/A
Tender offer solicitation (amended)
5 Mar 18
Latest ownership filings
SC 13G/A
Juno Therapeutics, Inc.
14 Feb 19
SC 13G/A
Juno Therapeutics, Inc.
9 Mar 18
SC 13G/A
Juno Therapeutics, Inc.
9 Mar 18
4
ROBERT NELSEN
7 Mar 18
4
Robert Azelby
7 Mar 18
4
ANTHONY B EVNIN
7 Mar 18
4
Bernard J Cassidy
7 Mar 18
4
Hal Barron
7 Mar 18
4
JAY T FLATLEY
7 Mar 18
4
SUNIL AGARWAL
7 Mar 18
Institutional ownership, Q2 2021
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 29.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Celgene Switzerland | 11.11 mm | $0.00 |
Arch Venture Fund VII | 10.55 mm | $0.00 |
Douglas K Bratton | 7.39 mm | $0.00 |